Abstract:Improving tumor immunogenicity is critical for increasing the responsiveness of triple-negative breast cancer (TNBC) to anti-PD-(L)1 treatment. Here, we verified that chidamide (CHI), an epigenetic modulator, could elicit immunogenic cell death within TNBC to enhance cancer immunogenicity and elicit an antitumor immune response. Additionally, CHI increased the expression level of PD-L1, MHC I, and MHC II on cancer cells, which contributed to T-cell recognition and PD-1/PD-L1 blockade therapy response. The synergistic antitumor efficacy of CHI and PD-L1 blockade therapy was further explored through liposomes co-delivering CHI and BMS-202 (a small-molecule PD-L1 inhibitor). The liposomes possessed good biocompatibility, security, and controllable drug release and endowed therapeutics drugs with favorable tumor accumulation. Furthermore, the drug-loaded liposomes could obviously boost the antitumor immunity of TNBC through CHI-enhanced tumor immunogenicity and BMS-202-mediated PD-L1 blockade, thereby effectively inhibiting the growth of primary and metastatic tumors with an inhibitory rate of metastasis of up to 96%. In summary, this work provided a referable and optional approach for clinical antitumor therapy based on the combination of an epigenetic modulator and PD-1/PD-L1 blockade therapy.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c08290.Cell viability of 4T1 cells treated with BMS-202 for 24 h; antitumor effect of in 4T1 tumor-bearing mice; analysis of H&E and PD-L1 in 4T1 tumor tissue treated with ; H&E examination of major organs in mice treated with CHI/; TUNEL and cleaved-caspase 3 expression analysis of a tumor in 4T1 tumor-bearing mice with different treatments; flow cytometric analysis of DC maturation in TDLNs treated with CHI/; IF analysis of CD4+ and CD8+ T cells in tumor tissue treated with CHI/; flow cytometric analysis of CD4+ and CD8+ T cells in the spleen treated with CHI/; flow cytometric analysis of NK cells in the spleen treated with CHI/; and EE and LE of CHI in the CHI–F127 complex (PDF)This article has not yet been cited by other publications.

Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation

Priming with LSD1 Inhibitors Promotes the Persistence and Antitumor Effect of Adoptively Transferred T Cells

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

LSD1 Silencing Contributes to Enhanced Efficacy of Anti-Cd47/pd-l1 Immunotherapy in Cervical Cancer.

Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy

E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC

Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC

Restoration of TFPI2 by LSD1 inhibition suppresses tumor progression and potentiates antitumor immunity in breast cancer

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade